E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Phase 2 Completed 51 enrolled Dana-Farber Cancer Institute Blood Cancer Research Partnership · collab Bristol-Myers Squibb · collab Celgene Corporation · collab Multiple Myeloma Research Consortium · collab The Leukemia and Lymphoma Society · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This research study is aimed to determine the proportion of high risk smoldering multiple myeloma patients who are progression free at 2 years after receiving elotuzumab, lenalidomide and dexamethasone combination therapy.

Timeline

Start: 2014-12-11
Primary completion: 2018-12-12
Completion: 2022-01-26

Publications

Kazandjian D, Diamond B, Papadimitriou M, Hill E, Sklavenitis-Pistofidis R, Ziccheddu B, Blaney P, Chojnacka M, Durante M, Maclachlan K, Young R, Usmani S, Davies F, Getz G, Ghobrial I, Korde N, Morgan G, Maura F, Landgren O. Genomic Profiling to Contextualize the Results of Intervention for Smoldering Multiple Myeloma. Clin Cancer Res. 2024 Oct 1;30(19):4482-4490. doi: 10.1158/1078-0432.CCR-24-0210.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dexamethasone	Small molecule	40 mg	Oral
Subject	Elotuzumab	Monoclonal antibody	10 mg/kg	Intravenous
Subject	Lenalidomide	Other / unclassified	25 mg	Oral

E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Summary

Timeline

Publications

Drugs

Indications